Why the study?
Does olmesartan medoxomil improve blood pressure control in patients with hypertension compared to other ARBs or placebo?
Does olmesartan medoxomil improve blood pressure control in patients with hypertension compared to other ARBs or placebo?
Olmesartan medoxomil is an effective, once-daily ARB with a favorable safety and pharmacokinetic profile for the treatment of hypertension.
Answers are grounded in this paper and cite their sources.
May support olmesartan preference in hypertension; leaves open confirmation via head-to-head RCTs.
Olmesartan medoxomil is a new angiotensin-II receptor antagonist for the treatment of hypertension. Olmesartan medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan has a dual method of elimination, with about 60% eliminated by the liver and the remainder by the kidney. In situations of impaired renal or hepatic function, the alternative excretion pathway can compensate for the compromised one. Olmesartan is not metabolized by the cytochrome P450 enzyme system and therefore has a low potential for metabolic drug interactions, a feature that may be of importance when treating patients on multiple drug regimens, such as the elderly. Olmesartan is well tolerated and has an excellent safety profile that is comparable to that of placebo. In addition, olmesartan provides 24-h blood pressure control with a once-daily dosing. In head-to-head studies, olmesartan delivered superior blood pressure reduction when compared with other angiotensin-II receptor antagonists at their recommended doses.
No takes yet. Share an insight, caveat, or question.
Brunner et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: